POZEN's CEO Presents At Update Conference (Transcript)

Tickers in this article: POZN

POZEN Inc. (POZN)

Update Conference Call

August 24, 2012 9:00 am ET

Executives

Stephanie Bonestell – Manager, Investor Relations & Public Relations

John R. Plachetka – Chairman, President, Chief Executive Officer

William L. Hodges – Chief Financial Officer, Senior Vice President-Finance and Administration

Elizabeth A. Cermak – Executive Vice President, Chief Commercial Officer

Analysts

Robert Hazlett – Roth Capital Partners LLC

Ken Trbovich – C. K. Cooper & Company

Presentation

Operator

Greetings and welcome to the POZEN’s Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Stephanie Bonestell with Investor Relations. Thank you, Ms. Bonestell, you may begin.

Stephanie Bonestell

Thank you, Rob, and good morning. On behalf of POZEN, I would like to welcome everyone to today's update conference call. By now, you should have received a copy of the company's press release. If you do not have it, you can access it on the home page of our website at www.pozen.com, where you can also access a replay of this conference call.

Before we begin, I need to remind you that various remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Such statements include any forecasts or assumptions about potential size or market opportunity, any observations that we may make about the expected timing and amounts of royalty payments from AstraZeneca and other revenue expected from our collaboration partners; the prospects for approval or timing of approval of any of our drug candidates or the way in which the FDA may consider our new drug applications or any particular clinical trial results; results relating to any pending litigation, future clinical trial plans and the likelihood of results of future trials and our potential commercialization plans, including potential sales and revenue forecasts for our product candidates or our ability to license our PA product candidate on terms and timing acceptable to us.

The adequacy of financial resources to accomplish our goals for future revenues are based on our current expectations and are subject to a number of risks and uncertainties, including our inability to know with certainty what standards the FDA will use to evaluate drug candidates and how that may change or evolve over time; how the FDA evaluates data; what the results of future trials may be, whether those trials will cost much more than we had estimated that they will cost or than they have historically cost; how the FDA weighs risks of drugs, including risks of drugs that have been in use for many years.